Connection

Hubert Schrezenmeier to Antibodies, Monoclonal, Humanized

Back to Details
This is a "connection" page, showing publications Hubert Schrezenmeier has written about Antibodies, Monoclonal, Humanized.
Hubert Schrezenmeier
Connection Strength
0.234
Antibodies, Monoclonal, Humanized
  1. Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients. Front Immunol. 2019; 10:1639.
    View in: PubMed
    Score: 0.042
  2. Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry. Am J Hematol. 2019 01; 94(1):E37-E41.
    View in: PubMed
    Score: 0.040
  3. Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial. Blood Adv. 2018 10 09; 2(19):2543-2549.
    View in: PubMed
    Score: 0.040
  4. Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. Blood Adv. 2018 09 11; 2(17):2176-2185.
    View in: PubMed
    Score: 0.040
  5. Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry. Intern Med J. 2017 Sep; 47(9):1026-1034.
    View in: PubMed
    Score: 0.037
  6. Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. Blood. 2017 02 23; 129(8):970-980.
    View in: PubMed
    Score: 0.035
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.